You are here: Industry Insights > AzurRx BioPharma

News List

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock firstwordpharma
July 23, 2021
AzurRx BioPharma, Inc. announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company.
AzurRx BioPharma Partners with Asymchem contractpharma
November 13, 2020
Will develop and produce MS1819 for the treatment of exocrine pancreatic insufficiency.
AzurRx, Delpharm Enter Manufacturing Agreement contractpharma
April 20, 2020
For the clinical drug product supply of MS1819 therapy for exocrine pancreatic insufficiency.
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer firstwordpharma
January 05, 2020
AzurRx BioPharma, Inc. (NASDAQ: AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that Daniel Schneiderman has been appointed to serve as the